This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
Thrombocytopenia dependent on platelet transfusions and diagnosed with platelet transfusion refractoriness.
Presence of one or more kinds of antiplatelet antibodies.
Male or female, age≥18 years.
The Eastern Cooperative Oncology Group (ECOG) physical status score ≤2.
Diagnosed with Idiopathic thrombocytopenic purpura.
Platelet transfusion refractoriness caused by non-immune factors.
Previously treated with the anti-CD38 monoclonal antibody.
Have an allergy to humanized monoclonal antibody or any part of CM313.